<\/p>\n\n\n\n
Legal basis:<\/strong> Article 17(1) of the MAR Regulation \u2013 Inside Information, 1:52 p.m.<\/p>\n\n\n\n Report content:<\/strong><\/p>\n\n\n\n The Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby announces that it has adopted a resolution regarding the allocation of a total of 55,000 Series A subscription warrants (the \u201cWarrants\u201d) under the Management Incentive Program for the year 2026.<\/p>\n\n\n\n Each Warrant entitles its holder to subscribe for one Series C share of the Company at an issue price of PLN 0.10 per share. The Warrants are issued pursuant to Resolution No. 7\/2021 of the Extraordinary General Meeting of the Company dated February 16, 2021, concerning the issuance of Series A subscription warrants, with the exclusion of pre-emptive rights of the existing shareholders, for the purpose of implementing incentive programs for members of the Management Board and other key personnel of the Company, entitling holders to subscribe for Series C shares, as well as the conditional increase of the Company\u2019s share capital through the issuance of Series C shares with the exclusion of existing shareholders\u2019 pre-emptive rights and the related amendment to the Company\u2019s Articles of Association.<\/p>\n\n\n\n The allocation of the Warrants was made pursuant to Resolution No. 6\/2021 of the Extraordinary General Meeting of the Company dated February 16, 2021, regarding the introduction of incentive programs for members of the Management Board and other key personnel of the Company, as well as pursuant to the Rules of the Incentive Program for Members of the Management Board of Celon Pharma S.A. for the years 2021\u20132030 (see Current Report No. 44\/2021), following the approval of the achievement of management objectives established in accordance with the provisions of those Rules.<\/p>\n","protected":false},"excerpt":{"rendered":"